Analysts predict that AngioDynamics, Inc. (NASDAQ:ANGO) will post earnings per share of $0.21 for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for AngioDynamics’ earnings, with the highest EPS estimate coming in at $0.21 and the lowest estimate coming in at $0.20. AngioDynamics reported earnings of $0.16 per share during the same quarter last year, which would suggest a positive year over year growth rate of 31.3%. The firm is scheduled to issue its next earnings results on Thursday, January 3rd.
On average, analysts expect that AngioDynamics will report full-year earnings of $0.85 per share for the current fiscal year. For the next fiscal year, analysts anticipate that the firm will post earnings of $0.99 per share, with EPS estimates ranging from $0.97 to $1.01. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover AngioDynamics.
AngioDynamics (NASDAQ:ANGO) last released its earnings results on Thursday, September 27th. The medical instruments supplier reported $0.16 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.02). The business had revenue of $85.34 million during the quarter, compared to analyst estimates of $84.05 million. AngioDynamics had a net margin of 4.62% and a return on equity of 5.44%. The business’s quarterly revenue was down .1% compared to the same quarter last year. During the same period last year, the business earned $0.13 EPS.
In other AngioDynamics news, CFO Michael Greiner sold 1,939 shares of the firm’s stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $21.53, for a total value of $41,746.67. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 2.80% of the company’s stock.
Large investors have recently made changes to their positions in the company. Granahan Investment Management Inc. MA grew its holdings in shares of AngioDynamics by 13.3% during the 2nd quarter. Granahan Investment Management Inc. MA now owns 468,099 shares of the medical instruments supplier’s stock worth $10,411,000 after purchasing an additional 54,794 shares in the last quarter. Chicago Equity Partners LLC grew its holdings in shares of AngioDynamics by 63.0% during the 2nd quarter. Chicago Equity Partners LLC now owns 66,535 shares of the medical instruments supplier’s stock worth $1,480,000 after purchasing an additional 25,710 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of AngioDynamics by 2.7% during the 1st quarter. Principal Financial Group Inc. now owns 298,168 shares of the medical instruments supplier’s stock worth $5,143,000 after purchasing an additional 7,871 shares in the last quarter. First Trust Advisors LP grew its holdings in shares of AngioDynamics by 18.2% during the 2nd quarter. First Trust Advisors LP now owns 41,709 shares of the medical instruments supplier’s stock worth $928,000 after purchasing an additional 6,414 shares in the last quarter. Finally, Tributary Capital Management LLC acquired a new stake in shares of AngioDynamics during the 2nd quarter worth approximately $9,681,000. 97.54% of the stock is currently owned by institutional investors.
ANGO traded down $0.51 during midday trading on Friday, reaching $21.38. The company’s stock had a trading volume of 107,142 shares, compared to its average volume of 238,178. The firm has a market capitalization of $789.95 million, a P/E ratio of 28.89 and a beta of 0.75. The company has a quick ratio of 1.55, a current ratio of 2.64 and a debt-to-equity ratio of 0.16. AngioDynamics has a twelve month low of $15.16 and a twelve month high of $24.49.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Featured Story: How to Invest in Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.